Ισραήλ - Αγγλικά - Ministry of Health

neopharm ltd, israel - ibuprofen - capsules liquid filled - ibuprofen 200 mg - ibuprofen - ibuprofen - for the relief of pain associated with headache, toothache, backache, muscular and menstrual pains. antipyretic. antiinflammatory for rheumatic diseases.for the treatment of pain assosiated with migraine.

Μάλτα - Αγγλικά - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cisplatin - concentrate for solution for infusion - cisplatin 1 mg - antineoplastic agents

Μάλτα - Αγγλικά - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Μάλτα - Αγγλικά - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - levofloxacin - solution for infusion - levofloxacin 5 mg/ml - antibacterials for systemic use

Μάλτα - Αγγλικά - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - levofloxacin - solution for infusion - levofloxacin 5 mg/ml - antibacterials for systemic use

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

mylan s.a.s - ribavirin - hepatitis c, chronic - antivirals for systemic use - ribavirin mylan is indicated for the treatment of chronic hepatitis c and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). ribavirin monotherapy must not be used.there is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).please refer also to the interferon alfa-2b summary of product characteristics (smpc) for prescribing information particular to that product.naïve patientsadult patientsribavirin mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hepatitis-c-virus (hcv) rna.children and adolescentsribavirin mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, and who are positive for serum hcv rna. when deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case-by-case basis (see section 4.4).previously treatment-failure patientsadult patientsribavirin mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis c who have previously responded (with normalisation of alt at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

recordati ireland ltd - silodosin - prostatic hyperplasia - urologicals - treatment of the signs and symptoms of benign prostatic hyperplasia (bph).

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

recordati ireland ltd - silodosin - prostatic hyperplasia - urologicals - treatment of the signs and symptoms of benign prostatic hyperplasia (bph)

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

pharma mar s.a. - trabectedin - ovarian neoplasms; sarcoma - antineoplastic agents - yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.yondelis in combination with pegylated liposomal doxorubicin (pld) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.